Genflow Biosciences plc has announced a development program in ophthalmology focused on advancing a novel gene therapy leveraging its proprietary centenarian SIRT6 (cSIRT6).

This initiative is part of Genflow's continued efforts to optimize its gene therapy and proprietary Centenarian SIRT6. As part of this effort, Genflow has signed a Material Transfer Agreement (MTA ...

The company's latest venture involves the use of its proprietary Centenarian SIRT6 (cSIRT6) gene technology, which will be delivered using a non-viral vector specifically designed for targeting ...

Genflow Biosciences Signs MSA with Heureka Labs, Launching AI-Powered Partnership in Gene Therapy Research LONDON, UNITED KINGDOM / ACCESS Newswire / April 14, 2025 / Genflow Biosciences Plc (LSE:GENF ...

Genflow has commenced a proof-of-concept clinical trial to evaluate the safety and efficacy of its proprietary SIRT6-centenarian gene therapy targeting age-related decline in dogs. The Company ...

The initial focus of the partnership will be to support Genflow’s lead gene therapy candidate, GF-1002, which is currently in preclinical evaluation and targets longevity through a centenarian variant ...

This initiative is part of Genflow's continued efforts to optimize its gene therapy and proprietary Centenarian SIRT6. As part of this effort, Genflow has signed a Material Transfer Agreement (MTA ...

The company’s latest venture involves the use of its proprietary Centenarian SIRT6 (cSIRT6) gene technology, which will be delivered using a non-viral vector specifically designed for targeting ocular ...

Genflow Biosciences Launches New Ophthalmology Development ProgramSigns MTA with Leading Ophthalmology Company LONDON, UK / ACCESS Newswire / April 10, 2025 / Genflow Biosciences Plc ...